



Datasheet for ABIN1881312
anti-ErbB2/Her2 antibody (pTyr1005)



[Go to Product page](#)

3 Images

3 Publications

Overview

Quantity:	400 µL
Target:	ErbB2/Her2
Binding Specificity:	pTyr1005
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This ErbB2/Her2 antibody is un-conjugated
Application:	Western Blotting (WB), Immunofluorescence (IF), Dot Blot (DB)

Product Details

Immunogen:	This ERBB2 Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding Y1005 of human ERBB2.
Clone:	RB41781
Isotype:	Ig Fraction
Purification:	This antibody is purified through a protein A column, followed by peptide affinity purification.

Target Details

Target:	ErbB2/Her2
Alternative Name:	ERBB2 (ErbB2/Her2 Products)
Background:	This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor

Target Details

tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.

Molecular Weight:	137910
NCBI Accession:	NP_001005862 , NP_004439
UniProt:	P04626
Pathways:	RTK Signaling , Fc-epsilon Receptor Signaling Pathway , EGFR Signaling Pathway , Neurotrophin Signaling Pathway , Skeletal Muscle Fiber Development

Application Details

Application Notes:	IF: 1:100. WB: 1:1000. DB: 1:500
Restrictions:	For Research Use only

Handling

Format:	Liquid
Buffer:	Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Preservative:	Sodium azide
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage:	4 °C,-20 °C
Expiry Date:	6 months

Publications


Product cited in: Xiang, Jiang, Liu, Zhang, Zhu: "hMan2c1 transgene promotes tumor progress in mice." in:

Transgenic research, Vol. 19, Issue 1, pp. 67-75, (2010) ([PubMed](#)).

Tian, Ju, Zhou, Liu, Zhu: "Inhibition of alpha-mannosidase Man2c1 gene expression suppresses growth of esophageal carcinoma cells through mitotic arrest and apoptosis." in: **Cancer science**, Vol. 99, Issue 12, pp. 2428-34, (2008) ([PubMed](#)).

Qu, Ju, Chen, Shi, Xiang, Zhou, Tian, Liu, Zhu: "Inhibition of the alpha-mannosidase Man2c1 gene expression enhances adhesion of Jurkat cells." in: **Cell research**, Vol. 16, Issue 7, pp. 622-31, (2006) ([PubMed](#)).

Images




Immunofluorescence

Image 1. Fluorescent confocal image of MCF7 cells stained with phospho-ERBB2- antibody. MCF7 cells were fixed with 4 % PFA (20 min), permeabilized with Triton X-100 (0.2 %, 30 min). Cells were then incubated with s phospho-ERBB2- primary antibody (1:100, 2 h at room temperature). For secondary antibody, Alexa Fluor® 488 conjugated donkey anti-rabbit antibody (green) was used (1:1000, 1h). Nuclei were counterstained with Hoechst 33342 (blue) (10 µg/mL, 5 min). Note the highly specific localization of the phospho-ERBB2- to the plasma membrane and cytoplasm.



Dot Blot

Image 2. Dot blot analysis of ERBB2 Antibody (Phospho) Phospho-specific Pab s on nitrocellulose membrane. 50 ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.6 µg per ml.



Western Blotting

Image 3. Western blot analysis of extracts from A431 cell, untreated or treated with EGF, using phospho-ERBB2- (left) or ErBB2 Antibody (right).